| 摘要 |
Disclosed is a use of a combination of donepezil hydrochloride, rivastigmine tartrate, galantamine hydrobromide, or memantine hydrochloride and a heterocyclic compound which is preferably selected from spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2’-indan], spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2’-(4’-fluoroindan)], spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2’-(5’-methoxyindan)], spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2’-(4’-cyanoindan)], spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2’-(4’-hydroxyindan)], and spiro[8-hydroxy-imidazo[1,2-a]pyridin-2(3H)-one-3,2’-indan] for the manufacture of a medicament for treating cognitive impairment selected from cerebrovascular disease, Lewy body dementia, Alzheimer’s disease, Parkinson’s disease, Pick’s disease, Huntington’s disease or Down’s syndrome, memory impairment due to aging. |
